Register free for our breaking news email alerts with analysis and cutting edge commentary from our award winning team. Registration only takes a minute.
Please see terms and conditions for restrictions on use of Citywire's Fund Manager database.

This Fund Manager Rating is based on the Citywire Long Only ratings methodology

Citywire Ratings are rewarded for risk adjusted outperformance of benchmarks we select independently More information on how Ratings are calculated

Steven Kornfeld

Steven Kornfeld

Showing manager performance in Belgium View performance globally

About Steven Kornfeld

Steven Kornfeld graduated from the Wharton School of Business at the University of Pennsylvania and Northwestern University’s Kellogg Graduate School of Management and holds a BA in business and an MBA. He has been managing funds for over ten years and is currently a fund manager at Franklin Templeton where he runs US equities. Before this he worked in private equity and previously as a sell-side research analyst where he specialised in emerging growth companies. Steven is a CFA Charterholder.

Are you Steven Kornfeld?

Citywire Rating: Not Eligible

Steven Kornfeld does not currently have the required track record to be eligible for a Citywire Rating. See methodology


  • JNot rated in Jul 2012
  • ANot rated in Aug 2012
  • SNot rated in Sep 2012
  • ONot rated in Oct 2012
  • NNot rated in Nov 2012
  • DNot rated in Dec 2012


Equity - Biotechnology
over : 31/03/2017 - 31/03/2018

Total Return

Month by Month Performance

Quarterly Performance

to 31/03/2018 Annual Q1 Q2 Q3 Q4
2018 -2.6%
2017 2.7% 10.6% -4.5% 4.9% -7.3%
2016 -15.4% -27.9% 4.2% 12.8% -0.2%
2015 12.8%

Related News

Franklin Templeton boosts blockbuster biotech team

US giant assigns third person to oversee dedicated equity investment vehicle, Citywire Selector learns.

Politics will not 'kill the golden goose', says biotech specialist

Franklin Templeton's Evan McCulloch is braced for potential disruption from Presidential race but believes idiosyncratic stories can stand up to the task.

Franklin Templeton reopens blockbuster biotech fund

US giant ends soft-close measures after 18-months following fall in assets under management and market correction.

Biotech manager departs Franklin Templeton

Sector specialist ends three-year stint on soft-closed strategy with pharma expert named as replacement, Citywire Global has learned.

Manager Tracker: festive changes revealed

With Christmas now upon us, Citywire Global reveals the manager moves to have hit our radar.

Citywire Discovery Source: Citywire Discovery Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated)..Portions of the information contained on this page was derived by Citywire Financial Publishers Ltd using content supplied by Lipper, A Reuters Company.